Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05975073 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
A Phase 1 study of MTAP-null Non-Small-Cell Lung Cancer and MTAP-null Solid Tumors, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 20
- Study locations
NCT05975073 is a Phase 1 study of MTAP-null Non-Small-Cell Lung Cancer and MTAP-null Solid Tumors that is active but no longer recruiting, run by Amgen. The registered enrollment target is 53 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT05975073, a Phase 1 study of MTAP-null Non-Small-Cell Lung Cancer and MTAP-null Solid Tumors, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the preliminary anti-tumor activity of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null Non-Small-Cell Lung Cancer (NSCLC).
Conditions Studied
Interventions
- DRUG AMG 193
- DRUG IDE397
Study Locations (20)
New York
- New York University Grossman School of Medicine and New York University Langone Hospitals - New York
- Columbia University Irving Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- University of Texas MD Anderson Cancer Center - Houston
- Next Oncology - Irving
Other
- Rigshospitalet - Copenhagen
- Seoul National University Bundang Hospital - Seongnam-si, Gyeonggi-do
California
- City of Hope National Medical Center - Duarte
Colorado
- Sarah Cannon Research Institute - Denver
Indiana
- Community Health Network MD Anderson Cancer Center - North - Indianapolis
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05975073
The ClinicalTrials.gov registry entry for NCT05975073 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with MTAP-null Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which AMG 193 is the first listed.
NCT05975073 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New York, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT05975073 about?
NCT05975073 is a clinical study titled "A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors". The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the p...
What is the current status of trial NCT05975073?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2023-08-01. Estimated completion is 2026-04-01.
What conditions does trial NCT05975073 study?
This clinical trial studies the following conditions: MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors.
What interventions are being tested in trial NCT05975073?
The interventions under investigation include: AMG 193 (DRUG), IDE397 (DRUG).
Who is sponsoring clinical trial NCT05975073?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05975073 being conducted?
This trial has 20 study locations across California, Colorado, Indiana, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
MTAP-null Non-Small-Cell Lung Cancer
All registered trials for this condition
MTAP-null Solid Tumors
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.